STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
· statnews.com · popularity 33/100 · 0 similar stories today
Read the original at statnews.com →
Summary
Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.
Found in: STAT News. Rating basis: single outlet; outlet tier 4; 1 feeds; feed position 4.